Symposium 19: Secretagogues: sulfonylureas and incretins
Symposium 19: Drug Treatment: What's New? Secretagogues: sulfonylureas and incretins Both SUs and iDPP4 have earned a spot within current Diabetes (DM) therapy. Regarding SUs, we refer to glimepiride, gliclazide and glipizide. Since glimepiride has lately been advised against, we will leave i...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Sello Editorial Lugones
2020-11-01
|
| Series: | Revista de la Sociedad Argentina de Diabetes |
| Subjects: | |
| Online Access: | https://revistasad.com/index.php/diabetes/article/view/353 |
| _version_ | 1811319223011508224 |
|---|---|
| author | Víctor Commendatore |
| author_facet | Víctor Commendatore |
| author_sort | Víctor Commendatore |
| collection | DOAJ |
| description | Symposium 19: Drug Treatment: What's New?
Secretagogues: sulfonylureas and incretins
Both SUs and iDPP4 have earned a spot within current Diabetes (DM) therapy. Regarding SUs, we refer to glimepiride, gliclazide and glipizide. Since glimepiride has lately been advised against, we will leave its qualities aside in neonatal DM treatment and MODY 3 to focus on its place within the schemes of T2D approach, answering the fundamental questions:
Are they still present in treatment guidelines? SAD 2016, WHO 2018, IDF 2019, NICE 2019, ALAD 2019, MSN 2020 and AACE-ACE 2020, among others, consider them an option to be used in monotherapy (if there is contraindication or metformin tolerance) or as a second or third association to T2D treatment . |
| first_indexed | 2024-04-13T12:39:00Z |
| format | Article |
| id | doaj.art-60c6c98793dc4011bf7b39fc58facc04 |
| institution | Directory Open Access Journal |
| issn | 0325-5247 2346-9420 |
| language | Spanish |
| last_indexed | 2024-04-13T12:39:00Z |
| publishDate | 2020-11-01 |
| publisher | Sello Editorial Lugones |
| record_format | Article |
| series | Revista de la Sociedad Argentina de Diabetes |
| spelling | doaj.art-60c6c98793dc4011bf7b39fc58facc042022-12-22T02:46:34ZspaSello Editorial LugonesRevista de la Sociedad Argentina de Diabetes0325-52472346-94202020-11-01543Sup777710.47196/diab.v54i3Sup.353287Symposium 19: Secretagogues: sulfonylureas and incretinsVíctor Commendatore0Hospital San Martín de Paraná, Entre Ríos, ArgentinaSymposium 19: Drug Treatment: What's New? Secretagogues: sulfonylureas and incretins Both SUs and iDPP4 have earned a spot within current Diabetes (DM) therapy. Regarding SUs, we refer to glimepiride, gliclazide and glipizide. Since glimepiride has lately been advised against, we will leave its qualities aside in neonatal DM treatment and MODY 3 to focus on its place within the schemes of T2D approach, answering the fundamental questions: Are they still present in treatment guidelines? SAD 2016, WHO 2018, IDF 2019, NICE 2019, ALAD 2019, MSN 2020 and AACE-ACE 2020, among others, consider them an option to be used in monotherapy (if there is contraindication or metformin tolerance) or as a second or third association to T2D treatment .https://revistasad.com/index.php/diabetes/article/view/353fármacosdiabetes mellitus tipo 2. |
| spellingShingle | Víctor Commendatore Symposium 19: Secretagogues: sulfonylureas and incretins Revista de la Sociedad Argentina de Diabetes fármacos diabetes mellitus tipo 2. |
| title | Symposium 19: Secretagogues: sulfonylureas and incretins |
| title_full | Symposium 19: Secretagogues: sulfonylureas and incretins |
| title_fullStr | Symposium 19: Secretagogues: sulfonylureas and incretins |
| title_full_unstemmed | Symposium 19: Secretagogues: sulfonylureas and incretins |
| title_short | Symposium 19: Secretagogues: sulfonylureas and incretins |
| title_sort | symposium 19 secretagogues sulfonylureas and incretins |
| topic | fármacos diabetes mellitus tipo 2. |
| url | https://revistasad.com/index.php/diabetes/article/view/353 |
| work_keys_str_mv | AT victorcommendatore symposium19secretagoguessulfonylureasandincretins |